Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.10    
    

Millennium Pharmaceuticals, Inc.

40 Landsdowne Street

Cambridge, Massachusetts 02139

617.679.7000

www.millennium.com 

Confidential
Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote such omissions. 

September
17, 2004 

Paul
Feirstein

ACS Sales and Marketing

Schering Corporation

2000 Galloping Hill Road

Kenilworth, NJ 07033 

	Re:
	Additional
Field Force Agreement — Amendment to Extend the Decision to Renew Joint Funding for 2005 

Dear
Paul: 

        Schering
and Millennium are parties to the Addendum to the Collaboration Agreement among Millennium Pharmaceuticals, Inc., Schering Corporation and Schering-Plough, Ltd., effective June
1, 2003 ("Additional Field Force Agreement"). Any defined terms used herein shall have the meaning set forth in the Additional Field Force Agreement. Pursuant to a discussion at the quarterly JSC
meeting on September 10, the JSC agreed to the following amendments to the Additional Field Force
Agreement in connection with the deadline to renew joint funding obligations for 2005 pursuant to Sections 4.1 and 2.4 of the Additional Field Force Agreement: 

	(1)
	To
extend the date for the 2005 renewal decision from September 30, 2004 to not later than [**].

	(2)
	In
the event the JSC elects not to renew the Additional Field Force Agreement for 2005, the sixty (60) day period referred to in Section 4.4 of the Additional Field Force Agreement
shall be reduced to thirty (30) days after such JSC decision.

	(3)
	In
the event the JSC elects to renew the Additional Field Force Agreement for 2005, the annual budget for Additional Field Force Expenses for 2005 to be agreed to under Section 3.4.2
of the Additional Field Force Agreement, shall be agreed upon by the JSC within thirty (30) days after such decision. 

        All
other terms and conditions of the Additional Field Force Agreement will remain in full force and effect. 

        Please
indicate your agreement to this Amendment by signing below and returning one fully executed original to my attention. 

Regards, 

	/s/ Grant Bogle
 Grant Bogle

VP, Sales & Marketingds	 	 	 

AGREED:

Schering
Corporation

    (for itself and on behalf of Schering-Plough Ltd.) 

	By:	/s/ Paul Feirstein
	 
	

Name(print):	

Paul Feirstein
	

 
	

Title:	

Vice President, ACS Sales & Marketing
	

 
	

Date:	

9/24/04
	

 

QuickLinks

Exhibit 10.10QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.11    
    

SCHERING CORPORATION

2000 Galloping Hill Road        Kenilworth, N.J. 07033

Telephone: (908) 298-4000

Confidential
Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote such omissions. 

November
30, 2004 

Mr.
Arthur Hiller

Senior Vice President, Sales & Marketing

Millennium Pharmaceuticals, Inc.

40 Landsdowne Street

Cambridge, Massachusetts 02139-4815 

	Re:
	Additional
Field Force Agreement — Further Amendment to Extend the Decision to Renew Joint Funding for 2005 

Dear
Mr. Hiller: 

        I
am writing with regard to the Addendum, effective June 1, 2003, to the 1995 Collaboration Agreement among Millennium Pharmaceuticals, Inc., Schering Corporation and Schering-Plough,
Ltd., including as such Addendum was previously amended (the "Additional Field Force Agreement"). 

        As
you are aware, Schering and Millennium previously agreed to extend until [**] the deadline for a decision by the JSC on whether or not to continue joint
funding of the Additional Field Force for the 2005 calendar year. In order to ensure that the parties reach a fully informed decision that reflects the best interests of both companies and the
product, Schering is willing to agree to a further extension of the deadline until the JSC meeting scheduled for December 6, 2004, as follows. 

        Any
capitalized terms that are not expressly defined herein shall have the meaning set forth in the Additional Field Force Agreement. 

        The
parties hereby agree to the following additional amendments to the Additional Field Force Agreement in connection with the deadline to renew joint funding obligations for 2005
pursuant to Sections 4.1 and 2.4 of the Additional Field Force Agreement: 

	(1)
	the
date for the 2005 renewal decision is further extended from [**] to not later than [**]. However, nothing in the Additional Field
Force Agreement or this Letter shall be construed as obligating either party to consider or agree to any further extension of this deadline.

	(2)
	In
the event the JSC elects not to renew the Additional Field Force Agreement for 2005, the sixty (60) day period referred to in Section 4.4 of the Additional Field Force Agreement
(and notwithstanding any previous amendments to such period) shall be replaced by the period beginning on the date of such JSC decision and ending on January 14, 2005.

	(3)
	The
parties agree that Schering will continue to share an equal (50:50) portion of any Additional Field Force Expenses incurred with respect to members of the Additional Field Force
that continue to be employed by Millennium during the period beginning on January 1, 2005 and ending on January 14, 2005.

	(4)
	In
the event the JSC elects to renew the Additional Field Force Agreement for 2005, the annual budget for Additional Field Force Expenses for 2005 to be agreed to under Section 3.4.2
of the Additional Field Force Agreement, shall be agreed upon by the JSC within sixty (60) days after such decision. 

        All
other terms and conditions of the Additional Field Force Agreement will remain in full force and effect. 

        Please
indicate your agreement to this Amendment by signing below and returning one fully executed original to my attention. 

	 	Regards,

SCHERING-CORPORATION

on behalf of itself and its Affiliate Schering-Plough Ltd.
	

 	

/s/ Margriet Gabriel-Regis
 Margriet Gabriel-Regis

Vice President

AGREED:

MILLENNIUM PHARMACEUTICALS, INC. 

	By:	/s/ A. J. Hiller
	 
	

Name(print):	

A. J. Hiller
	

 
	

Title:	

Senior Vice President
	

 

QuickLinks

Exhibit 10.11QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.12(b)    
    

Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.  

Millennium
Pharmaceuticals, Inc.

40 Landsdowne Street

Cambridge

Massachusetts

USA 

Date:
28-02-2005 

Dear
Sirs 

We
refer to the License, Development and Commercialisation Agreement between us dated 22 June, 2004 ("the Agreement") and in particular to Clause 8.1 (b) (i) of the Agreement. The
capitalized terms used in this Letter, which are defined in the Agreement, will have the meanings given to them in the Agreement. 

Notwithstanding
the fact that the Transition Activities and Processes have not yet been completed by Millennium, the parties have agreed that GSK will pay to Millennium the milestone payment of
nineteen million nine hundred thousand dollars (USD $19,900,000) referred to in Clause 8.1 (b) (i), given the fact that: 

	(i)
	the
Agreement is in full force and effect on and after January 1st, 2005;

	(ii)
	the
CMA has transferred to GSK; and

	(iii)
	GSK
has achieved [**] dollars of gross sales of the Licensed Product in the Territory. 

Such
payment will be made by GSK within thirty (30) days of receipt by GSK of an invoice for the said amount from Millennium. 

Millennium
specifically hereby agrees to continue to ensure that the Transition Activities and Processes will be completed in accordance with the terms of the Agreement to the extent that they have
not been completed at the date of signing this letter and that payment of the sum nineteen million nine hundred thousand dollars (USD $19,900,000) in accordance with the above shall not relieve it of
any of its obligations in this respect. 

Please
confirm your consent to the above by signing and returning the enclosed duplicate copy of this letter initially by fax to Mary Kerr (Fax number +44 (0) 208 047 6958) and Lawrence DeGraaf
(Fax number 919 5499074) and thereafter in hard copy form to Lawrence DeGraaf at GlaxoSmithKline, 5 Moore Drive, PO Box 13398, Research Triangle Park, North Carolina 27709-3398. 

Yours
faithfully 

For

GLAXO GROUP LIMITED 

/s/
Mary Kerr    28/2/05 

Mary
Kerr

VP Critical Care Business Unit, Pharma Europe, GlaxoSmithKline 

Agreed
and accepted

/s/ Arthur J. Hiller 4/3/05

Arthur J. Hiller, SVP

For MILLENNIUM PHARMACEUTICALS, INC 

QuickLinks

Exhibit 10.12(b)QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.18    
    

Millennium Pharmaceuticals, Inc.

Description of Non-Employee Director Compensation  

        We do not pay directors who are also Millennium employees any additional compensation for their service as a director. We do pay our non-employee
directors for their service as directors. 

        Each
year, the Board Governance Committee reviews the compensation we pay to our non-employee directors. The Committee compares our Board compensation to compensation paid to
non-employee directors by similarly sized public companies in similar businesses. The Committee also considers the responsibilities that we ask our Board members to assume and the amount
of time required to perform those responsibilities. 

        Below
we show the rate of compensation that we pay to our non-employee directors effective January 1, 2005. 

Cash Compensation  

        Each director who is not an employee of Millennium receives: 

	Type of Fee
 
	 	Amount
	 	For each

	Annual retainer:	 	$	25,000	 	Year of service
	
Additional annual retainer for lead outside director:	
 	
$	

10,000	
 	

Year of service
	
Attendance:	
 	
$	

2,000	
 	

Board meeting attended in person
	

 	
 	
$	

1,000	
 	

Board meeting attended by conference telephone
	

 	
 	
$	

1,000	
 	

Board committee meeting attended in person
	

 	
 	
$	

750	
 	

Board committee meeting attended by conference telephone

        Millennium
also reimburses non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with their service as
directors. 

Stock Compensation  

        Directors also participate in our 2000 Stock Incentive Plan. Under the option program for directors adopted by the Board, our non-employee directors
receive stock option grants as follows: 

	 
	 	Number

of shares
	 	Granted in three

installments on
	 	Vesting

Schedule

	Initial Option Grant:	 	35,000	 	the date the director is first elected, one month later and two months later	 	vest on a monthly basis beginning one month from the date of election and become fully vested on the fourth anniversary of the date of election
	
Annual Option Grant:	
 	

15,000	
 	

May 1st, June 1st and July 1st of each year, prorated for service on the Board of less than one year	
 	

vest on a monthly basis beginning as of June 1st in the year granted and become fully vested on May 1st of the fourth year after the grant date
	
Committee Chair:	
 	

500	
 	

the dates of the annual option grant	
 	

same as annual grant
	
Lead Outside Director:	
 	

5,000	
 	

the dates of the annual option grant	
 	

same as annual grant

        Each
option terminates on the earlier of ten years after the date of grant or the date 90 days after the option holder ceases to serve as a director or employee (or one year in
the case of disability and three years in the event of death). 

        Under
the 2000 Plan, an option becomes fully vested in the event of the death of the director. The exercise price of options granted under the 2000 Plan is equal to the closing price of
Millennium common stock as quoted on the NASDAQ stock market on the date of grant. 

QuickLinks

Exhibit 10.18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]